POD primarily affects two populations: children aged 6 months to 16 years old, with boys and girls both affected, and women ages 17–45 years old (Sneddon, 1972; Wilkinson, Kirton, & Wilkinson ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed ...

The FDA has approved Ebglyss (lebrikizumab-lbkz), a new biologic treatment for moderate-to-severe atopic dermatitis in people ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional ...

Contact dermatitis is a form of eczema. Contact dermatitis results from skin contact with an irritant substance or antigen. It is not the same thing as atopic dermatitis, which is caused by internal ...

I have got very noticeable lines underneath my eyes. If I pull the skin downwards, the lines go. What treatment can I have to either erase them or plump them out? The rest of my face hardly has a ...

Shea butter deeply moisturises, while coconut oil helps smooth fine lines. Combine equal parts and apply around the eyes to hydrate and reduce the appearance of wrinkles naturally. Vitamin E oil ...

One study identified 19 patients with atopic dermatitis in a case series of 20 patients with POD (Beacham, Kurgansky, & Gould, 1990). Others found that 14% of pediatric POD cases had atopic ...

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...

The most common side effects of EBGLYSS include eye and eyelid inflammation ... with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used ...

EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients treated with EBGLYSS experienced significant skin ...